血清可溶性转铁蛋白受体在儿童铁缺乏中的应用

目的　探讨血清可溶性转铁蛋白受体 (sTfR)的检测在儿童铁缺乏诊断中的应用价值。方法　测定正常对照组 (5 0名 )和患儿组 (10 8例 )血红蛋白、sTfR以及有关铁参数。结果　sTfR静脉血、手指血检测结果经统计呈高度相关 (P <0 .0 0 1)。正常对照组、缺铁性贫血组和非缺铁性贫血组的sTfR测定结果分别为 (1.31± 0 .33)mg/L、(9.6 7± 6 .97)mg/L和 (1.79± 1.14 )mg/L ;缺铁性贫血组的sTfR与其他各组比较差异有显著性 (P <0 .0 1)。以 3.2mg/L为临界值 ,sTfR在未确定病因的贫血组和非贫血组中的阳性率分别为 34.6 %和15 .9%。随访的 5例缺铁性贫血患儿治疗前后sTfR检测结果差异有显著性 (P <0 .0 5 )。结论　血清sTfR检测可用于诊断和鉴别诊断缺铁性贫血与非缺铁性贫血 ,反映儿童铁缺乏的状况 ,作为疗效监测的指标。sTfR可用手指血检测 ,尤其适合儿科临床应用     

可溶性转铁蛋白受体在铁缺乏疾病诊断中的应用

目的探讨可溶性转铁蛋白受体(sTfR)检测在鉴别缺铁性贫血(IDA)和非缺铁性贫血(ACD)诊断中的意义.方法以免疫比浊法测定IDA和ACD患者和正常对照组血清中sTfR水平.结果正常对照组血清中sTfR水平为0.96～2.32 mg/L,中位数为1.55 mg/L;ACD组血清中sTfR水平为0.99～2.48 mg/L,中位数为1.84 mg/L;IDA组血清中sTfR水平为1.58～8.79 mg/L,中位数为4.30 mg/L.以ACD组中患者最高值2.50 mg/L为判断限,sTfR对诊断IDA的特异性为100%;灵敏度为95%.结论以sTfR2.50 mg/L为判断限,对鉴别IDA和ACD有明显的临床诊断意义.     

可溶性转铁蛋白受体在铁缺乏疾病诊断中的应用

目的　探讨可溶性转铁蛋白受体 (sTfR)检测在鉴别缺铁性贫血 (IDA)和非缺铁性贫血 (ACD)诊断中的意义。方法　以免疫比浊法测定IDA和ACD患者和正常对照组血清中sTfR水平。结果　正常对照组血清中sTfR水平为 0 .96～ 2 .3 2mg/L,中位数为 1.5 5mg/L;ACD组血清中sTfR水平为 0 .99～ 2 .48mg/L,中位数为1.84mg/L;IDA组血清中sTfR水平为 1.5 8～ 8.79mg/L,中位数为 4.3 0mg/L。以ACD组中患者最高值2 .5 0mg/L为判断限 ,sTfR对诊断IDA的特异性为 10 0 % ;灵敏度为 95 %。结论　以sTfR 2 .5 0mg/L为判断限 ,对鉴别IDA和ACD有明显的临床诊断意义     

缺铁性贫血治疗后血清可溶性转铁蛋白受体测定结果分析

目的　探讨血清可溶性转铁蛋白受体 (S TfR)在缺铁性贫血治疗前后的变化及意义。方法　对 2 2例缺铁性贫血的小儿进行 6周补铁治疗 ,分别于治疗前 ,治疗 2、4、6周后ELISA法测定s TfR ,同时检测Hb、血清铁蛋白 (SF)。结果　治疗 2周后s TfR降低、Hb升高 ,均较治疗前明显变化 ;SF 4周后方有上升 ,与治疗前比较差异显著 ;6周后各指标均至正常范围。结论　s TfR在缺铁性贫血补铁治疗后迅速降低 ,可作为评价缺铁性贫血治疗效果的指标。     

可溶性转铁蛋白受体在缺铁性贫血中的临床应用

目的 阐述可溶性转铁蛋白受体在缺铁性贫血中的临床应用.方法 采用免疫透射比浊法定量检测缺铁性贫血(IDA)组、慢性病贫血(ACD)组和正常对照组的血清可溶性转铁蛋白受体(sTfR)水平,并结合MCV和RDW这两个血常规指标对结果进行分析比较.结果 IDA组:sTfR(5.50±0.22)mg/L,RDW(19.4± 6.2)%,MCV(71.7±12.8)fl;对照组:sTfR(1.30±0.41)mg/L,RDW(13.1±1.3)%,MCV(85.0±4.5)fl;ACD组:sTfR(1.16±0.54)mg/L,RDW(16.3± 4.0)%,MCV(84.6±13.6)fl.IDA组sTfR,RDW均高于对照组,与ACD组比较差异具有统计学意义(P<0.05),MCV则显著低于对照组及ACD组(P<0.05).ACD组的sTfR和MCV值与正常对照组比较差异无统计学意义(P>0.05),而RDW则高于正常对照组.结论 sTfR是一个灵敏、可靠的缺铁诊断的定量指标,较MCV,RDW更适用于对IDA和ACD的鉴别诊断以及在危险人群的铁状况评估方面具有重要的临床价值.     

贫血患者血清可溶性转铁蛋白受体的变化

贫血患者血清可溶性转铁蛋白受体的变化王伟良李蓉生李琦我们采用酶联免疫吸附试验（ＥＬＩＳＡ）方法对临床明确诊断的７７例贫血患者血清可溶性转铁蛋受体（ｓＴｆＲ）含量进行测定，以观察其在贫血诊断中的临床意义。病例和方法１临床标本１５名正常志愿者均为本院健康...     

血清可溶性转铁蛋白受体／铁蛋白比率在贫血鉴别诊断中的临床应用

目的探讨血清中可溶性转铁蛋白受体（sTfR）与铁蛋白（SF）在缺铁性贫血（IDA）和慢性病贫血（ACD）鉴别诊断的价值。方法采用乳胶增强动态定时散射比浊法定量检测IDA组、ACD组、ACD合并缺铁（ACD＋ID）组和健康对照组sTfR和SF水平及其比率，并进行比较。结果IDA组、ACD＋ID组sTfR水平和sTfR／SF比率显著高于对照组及ACD组（P〈0．05），SF水平明显低于对照组及ACD组（P〈0．05）。ACD组sTfR、SF水平及sTfR／SF比率与正常对照组比较差异无统计学意义（P〈0．05）。结论血清sTfR／SF比率对IDA和ACD的鉴别诊断具有重要的临床应用价值。     

可溶性转铁蛋白受体在糖尿病患者诊断中的价值

目的探讨可溶性转铁蛋白受体水平对糖尿病患者在鉴别缺铁性贫血（IDA）和非缺铁性贫血（ACD）诊断中的意义。方法采用散射比浊检测技术检测sTfR水平。结果糖尿病患者-IDA组sTfR水平显著高于对照组（P〈0．01）；糖尿病患者．IDA组也显著高于糖尿病患者．普通组与糖尿病患者-ACD组（P〈0．05）。结论sTfR在缺铁性贫血和慢性疾病继发性贫血的鉴别诊断上有明显的临床意义。     

转铁蛋白受体与铁缺乏的诊断

转铁蛋白受体（ＴｆＲ）是一种跨膜糖蛋白,测定可溶性转铁蛋白受体（ＳＴｆＲ）血清水平在缺铁性贫血的诊断及鉴别中的作用日益受到重视。本文综述了 ＴｆＲ的分子结构及其功能,ＳＴｆＲ的实验室检测及临床应用,提示测定ｓＴｆＲ血清水平对鉴别诊断铁缺乏,反映骨髓红细胞系统增生情况等方面有重要价值。     

转铁蛋白受体与铁缺乏的诊断

转铁蛋白受体（ＴｆＲ）是一种跨膜糖蛋白，测定可溶性转铁蛋白受体（ｓＴｆＲ）血清水平在缺铁性贫血的诊断及鉴别中的作用日益受到重视。本文综述了ＴｆＲ的分子结构及其功能；ｓＴｆＲ的实验室检测及临床应用，提示测定ｓＴｆＲ血清水平对鉴别诊断铁缺乏，反映骨工细胞系统增生情况等方面有重要价值。     

转铁蛋白受体指数对儿童贮存铁减少的诊断价值

目的探讨转铁蛋白受体指数[血清转铁蛋白受体（sTfR）／Log血清铁蛋白（SF）]对儿童贫血早期贮存铁减少（IDS）诊断的有效性。方法检测568例武汉地区来我院的就诊儿童和96名健康儿童的锌原卟啉（ZPP）、血红蛋白（Hb）、血清铁蛋白（sF）、血清转铁蛋白受体（sTfR）水平。依评价标准,分为铁正常、IDS、红细胞生成缺铁（IDE）与缺铁性贫血（IDA）4组。统计IDS儿童数量,并计算其sTfR／LogSF。采用受试者工作特征（ROC）曲线分析sTfR、sTfR／LogSF诊断儿童IPS的效率。结果筛查出的102例IDS儿童与健康儿童相比,血清sTfR和sTfR／LogSF均显著增加（P〈0．05）。但对贫血早期儿童IDS的诊断而言。sTfR／LogSF的灵敏度、特异性、阳性预测值和阴性预测值均高于sTfR。经ROC曲线分析,sTfR诊断IDS的效率为0．79,而sTfR／LogSF诊断IDS的效率达0．93。结论sTfR／LogSF能有效反映儿童早期贮存铁的情况,可作为筛查儿童IDS的可靠指标。     

可溶性转铁蛋白受体在缺铁性贫血诊断中的临床应用价值

目的探讨血清可溶性转铁蛋白受体(sTfR)在缺铁性贫血(IDA)诊断中的临床应用价值。方法选择正常对照组和IDA患者组各58例,同等条件下对2组sTfR、血清铁(Fe)、总铁结合力(TIBC)、转铁蛋白饱和度(TS)、转铁蛋白(Tf)、血清铁蛋白(SF)、血红蛋白(Hb)、平均红细胞容积(MCV)、平均红细胞血红蛋白量(MCH)、平均红细胞血红蛋白浓度(MCHC)、红细胞体积分布宽度(RDW)等指标进行定量检测,并分别行t检验和ROC曲线分析。结果 IDA组血清sTfR浓度为(46.40±9.43)nmol/L,正常对照组的sTfR浓度为(15.45±2.95)nmol/L,与对照组比较,IDA组血清sTfR明显升高,差异具有统计学意义(P<0.01)。用于IDA诊断时,sTfR的ROC曲线下面积达0.971(P<0.01)。结论血清sTfR浓度可较准确反映铁贮存状况,对IDA的诊断具有一定的临床实用价值。     

Increased serum soluble transferrin receptor concentration detects subclinical iron deficiency in healthy adolescent girls.

The objective of this study was to investigate whether the measurement of serum soluble transferrin receptor could detect subclinical iron deficiency in adolescent girls, and to assess the possible specificity-compromising effects of growth, menarche, and intensive physical activity. The study population consisted of 191 physically active (control) girls aged 9-15 years. Dietary iron intake was estimated at baseline, and after 6 and 12 months. Iron status of the subjects was assessed by haematological laboratory tests at 6 and 12 months. A 3-month iron and multivitamin supplementation was started after the visit at 6 months. The supplementation consistently decreased soluble transferrin receptor concentrations in subjects with initial values greater than 2.4 mg/l, which was determined by regression analysis to be the cut-off value for iron-deficient erythropoiesis. The 95% reference interval in the iron-replete subjects (0.9-2.4 mg/l) was consistent with this finding. In our population, the incidence of subclinical iron deficiency was 10%. Growth or physical activity had no effect on the iron status. This study shows that, similarly to adults, soluble transferrin receptor measurement can be used to detect subclinical iron deficiency in adolescents (competitive athletes or normal controls). We suggest that soluble transferrin receptor concentrations above 2.4 mg/l indicate clinically relevant iron deficiency in adolescents.     

The use of soluble transferrin receptor to assess iron deficiency in adults with cystic fibrosis

BACKGROUND: Iron deficiency (ID) is common in cystic fibrosis (CF) and the soluble transferrin receptor (sTfR) is a sensitive, quantitative measurement of tissue iron deficiency. The study investigated the use of sTfR together with serum iron, transferrin saturation (TS) and serum ferritin, in assessing iron status in adult CF patients. METHODS: The patient population consisted of 127 CF patients which consisted of 51 inpatients with infected exacerbation (IE) and 76 outpatients at the time of their annual review (AR). Serum sTfR was measured using a particle-enhanced immunoturbidimetric assay on the Beckman Coulter LX20. RESULTS: Sixty five percent (65%) of CF patients in the IE group and 28% in the AR group had ID as determined TS, but only 18% (IE group) and 20% (AR group) as determined by ferritin. Serum sTfR detected 20% in the IE group and 12% in the AR group. We found significant correlation between C-reactive protein and TS (r=-0.56; P<0.01) but not with ferritin (r=0.22; P=0.380) in the IE group. CONCLUSION: Iron status of patients with CF can be accurately assessed by sTfR which is unaffected by the acute phase response and can be used in conjunction with serum ferritin.     

可溶性转铁蛋白受体检测对非成年人缺铁性贫血的诊断价值

目的：探讨可溶性转铁蛋白受体（sTfR）对非成年人缺铁性贫血（IDA）的诊断价值及其与慢性病贫血（ACD）的鉴别诊断价值。方法 IDA 组26例,男12例,女14例,年龄1月至15．5岁;ACD 组33例,男17例,女16例,年龄2月至14．0岁;对照组30例,男15例,女15例,年龄1月至15．5岁。sTfR、铁蛋白（SF）检测方法为免疫比浊法,血清铁（SI）为亚铁嗪比色法。结果各组患儿的性别比例、年龄无显著性差异;ACD 组的 SI 均值介于 IDA 组和对照组之间;IDA 组的 SF 显著低于 ACD 组（P ＜0．001）和对照组（P ＜0．001）,而 sTfR 显著高于 ACD 组（P ＜0．001）和对照组（P ＜0．001）。sTfR 鉴别诊断 IDA 和 ACD 的截值为3．56 mg/L,其敏感性、特异性、阴性预测值、阳性预测值、准确性分别为95．12％、93．92％、94．11％、97．53％、95．50％。结论sTfR 对 IDA 具有较高的敏感性及特异性,有助于诊断 IDA 及鉴别诊断 ACD。     

Soluble transferrin receptor and transferrin receptor-ferritin index in iron deficiency anemia and anemia in rheumatoid arthritis.

The aim of the study was to evaluate the clinical efficiency of soluble transferrin receptor and transferrin receptor-ferritin index (sTfR/logF) in the diagnosis of iron deficiency anemia, as well as the differential diagnosis of iron deficiency anemia and anemia in rheumatoid arthritis. The study included 96 patients with anemia and 61 healthy volunteers as a control group. In healthy subjects there were no significant sex and age differences in the parameters tested. The study results showed these parameters to be reliable in the diagnosis of iron deficiency anemia, as well as in the differential diagnosis of iron deficiency anemia and anemia of chronic disease. The results indicate that sTfR/logF could be used to help differentiate coexisting iron deficiency in patients with anemia of chronic disease. Receiver operating characteristic analysis showed a higher discriminating power of transferrin receptor-ferritin index vs. soluble transferrin receptor in the diagnosis of iron deficiency anemia, as well as in the differential diagnosis between iron deficiency anemia and anemia of chronic disease. In patients with anemia in rheumatoid arthritis, the parameters tested showed no significant differences with respect to C-reactive protein concentration. These results suggested that the parameters tested are not affected by acute or chronic inflammatory disease.     

Usefulness of soluble transferrin receptor and ferritin in iron deficiency and chronic disease

Soluble transferrin receptor (sTfR) is a biochemical parameter used for the detection of iron deficiency in situations where ferritin has limited diagnostic value owing to the present chronic disease. The sTfR concentration was determined in 118 patients divided according to their inflammatory status and underlying disease into groups of patients with iron‐deficiency anemia (IDA), anemia of chronic disease (ACD) and patients with a coexisting state of iron deficiency and anemia of chronic disease (ID+ACD). All patients with iron deficiency had elevated sTfR levels, but ferritin concentrations were normal or increased in patients with inflammatory characteristics. Diagnostic efficiencies of sTfR, sTfR/log ferritin index (sTfR/F) and ferritin were evaluated by receiver operating characteristic curve (ROC) analysis. According to the results obtained, the best diagnostic efficiency for differential diagnosis of anemic patients with iron deficiency compared to the control group had a sTfR concentration (0.884) that was significantly higher than ferritin (0.638), but not higher than the calculated ratio sTfR/F (0.820). The cut‐off value of the sTfR/F index differentiating the best control group from the IDA and ID+ACD groups was 1.30, and for differentiation of ACD from IDA and ID+ACD, the value was 0.90. Soluble transferrin receptor is an additional parameter to ferritin for the diagnosis of IDA and differential diagnosis of ID+ACD, but calculation of the sTfR/F index did not improve the diagnostic value of determining sTfR alone.     

Usefulness of soluble transferrin receptor and ferritin in iron deficiency and chronic disease

Soluble transferrin receptor (sTfR) is a biochemical parameter used for the detection of iron deficiency in situations where ferritin has limited diagnostic value owing to the present chronic disease. The sTfR concentration was determined in 118 patients divided according to their inflammatory status and underlying disease into groups of patients with iron-deficiency anemia (IDA), anemia of chronic disease (ACD) and patients with a coexisting state of iron deficiency and anemia of chronic disease (ID+ACD). All patients with iron deficiency had elevated sTfR levels, but ferritin concentrations were normal or increased in patients with inflammatory characteristics. Diagnostic efficiencies of sTfR, sTfR/log ferritin index (sTfR/F) and ferritin were evaluated by receiver operating characteristic curve (ROC) analysis. According to the results obtained, the best diagnostic efficiency for differential diagnosis of anemic patients with iron deficiency compared to the control group had a sTfR concentration (0.884) that was significantly higher than ferritin (0.638), but not higher than the calculated ratio sTfR/F (0.820). The cut-off value of the sTfR/F index differentiating the best control group from the IDA and ID+ACD groups was 1.30, and for differentiation of ACD from IDA and ID+ACD, the value was 0.90. Soluble transferrin receptor is an additional parameter to ferritin for the diagnosis of IDA and differential diagnosis of ID+ACD, but calculation of the sTfR/F index did not improve the diagnostic value of determining sTfR alone.     

Increased serum transferrin saturation is associated with lower serum transferrin receptor concentration

BACKGROUND: Serum transferrin receptor (sTfR) concentrations are increased in iron deficiency. We wished to examine whether they are decreased in the presence of potential iron-loading conditions, as reflected by increased transferrin saturation (TS) on a single occasion. METHODS: We compared sTfR concentrations between 570 controls with normal iron status and 189 cases with increased serum TS on a single occasion; these latter individuals may be potential cases of iron overload. Cases and controls were selected from adults who had been examined in the third National Health and Nutrition Examination Survey (1988-1994) and for whom excess sera were available to perform sTfR measurements after the survey's completion. Increased TS was defined as >60% for men and >55% for women; normal iron status was defined as having no evidence of iron deficiency, iron overload, or inflammation indicated by serum ferritin, TS, erythrocyte protoporphyrin, and C-reactive protein. RESULTS: Mean sTfR and mean log sTfR:ferritin were approximately 10% and 24% lower, respectively, in cases than in controls (P <0.002). Cases were significantly more likely to have an sTfR value <2.9 mg/L, the lower limit of the reference interval, than were controls (odds ratio = 1.8; 95% confidence interval, 1.04-2.37). CONCLUSION: Our results support previous studies that suggested that sTfR may be useful for assessing high iron status in populations.